Full TitleMyeloablative Unrelated Donor Cord Blood Transplantation with T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients with High Risk Hematological Malignancies
Stem cell transplantation is often used in patients with hematologic cancers who have had chemotherapy to help rebuild their blood-forming and immune systems. But not every patient has a stem cell donor who is a close enough genetic match.
In these cases, doctors may use umbilical cord blood, which is a rich source of stem cells. Cord blood collections from two newborns (a “double-unit” transplant) can be used to increase the number of cord blood cells patients receive, further enhancing their recovery. But even in this case, recovery can take a long time.
The purpose of this study is to see if recovery during the first few weeks after transplantation can be enhanced by using double-unit cord blood transplantation followed by an infusion of blood stem cells from a close relative in patients with hematological cancers that are advanced or at high risk of relapse. To prevent a potential complication of transplantation known as graft-versus-host disease (where the white blood cells from the donor attack the recipient’s tissues), T cells will be removed from the relative’s stem cells before giving them to the patient. This is known as “T-cell depletion.”
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of an acute leukemia with a high risk of relapse, chronic leukemia that has progressed or reached blast crisis, advanced myelodysplastic syndrome, or aggressive lymphoma.
- Patients must have a close relative who can serve as a donor of stem cells.
- This study is open to patients aged 2 to 70.
For more information and to inquire about eligibility for this study, please contact Dr. Juliet Barker at 212-639-3468.